The evolution in our understanding of Opioid receptors and their subtypes is intimately linked to the development of new pharmacological treatments for diseases and disorders as diverse as addiction, self-injurious behavior, pain, cancer, inflammation, eating disorders, traumatic injury, pruritis and movement disorders. The contributions contained in Opioid Receptors and Antagonists: From Bench to Clinic represent efforts from leading international scientists and clinicians making use of the latest information emerging from the study of the opioid-receptor system. The authors use a variety of experimental and clinical approaches involving the fields of molecular biology, biochemistry, anatomy, pharmacology, behavioral neuroscience and psychiatry to illustrate rapidly developing experimental and therapeutic areas. Highlights include characterization of opioid receptors, chemistry and pharmacology of opiod antagonists for various receptor subtypes (Mu, Kappa, and Delta), discussion of therapeutic uses of opiod antagonists and exploration of innovative approaches to therapeutic drug delivery.
Opioid Receptors and Antagonists: From Bench to Clinic offers a comprehensive view of recent work on opiod antagonist applications and uses in various clinical treatments. Emphasis is placed on disorders of the reward system. This volume serves as reference while also illuminating prospects for future research.
Author(s): Lindsay H. Burns, Todd W. Vanderah, Hoau-Yan Wang (auth.), Reginald L. Dean III, Edward J. Bilsky, S. Stevens Negus (eds.)
Series: Contemporary Neuroscience
Edition: 1
Publisher: Humana Press
Year: 2009
Language: English
Pages: 757
Tags: Pharmacology/Toxicology
Front Matter....Pages i-xxiii
Ultra-Low-Dose Opioid Antagonists Enhance Opioid Analgesia and Reduce Tolerance....Pages 3-17
Upregulation of Opioid Receptors....Pages 19-44
Imaging Human Brain Opioid Receptors: Applications to Substance Use Disorders....Pages 45-65
Opioid Receptor Antagonist-Mediated Signaling in the Immune System....Pages 67-80
The Chemistry and Pharmacology of μ-Opioid Antagonists....Pages 83-97
Medicinal Chemistry of Kappa Opioid Receptor Antagonists....Pages 99-118
The Chemistry and Pharmacology of Delta Opioid Antagonists....Pages 119-136
Novel Opioid Antagonists with Mixed/Dual Selectivity....Pages 137-151
Experimental Utility and Clinical Potential of Irreversible Opioid Antagonists....Pages 153-174
Methylnaltrexone: A Peripherally Acting Opioid Antagonist....Pages 175-198
Opioid Antagonist Effects in Animal Models Related to Opioid Abuse: Drug Discrimination and Drug Self-Administration....Pages 201-226
Naltrexone for Initiation and Maintenance of Opiate Abstinence....Pages 227-245
Ultra-Low-Dose Naltrexone Decreases Dependence and Addictive Properties of Opioids....Pages 247-261
Can a Combination Formulation Containing a Neutral Opiate Antagonist Decrease the Abuse of μ-Agonist Opiates....Pages 263-272
Effects of Opioid Antagonists on the Abuse-Related Effects of Psychomotor Stimulants and Nicotine....Pages 273-298
Potential Use of Opioid Antagonists in the Treatment of Marijuana Abuse and Dependence....Pages 299-314
Naltrexone in Smoking Cessation: A Review of the Literature and Future Directions....Pages 315-332
Opioid Antagonists and Ethanol's Ability to Reinforce Intake of Alcoholic Beverages: Preclinical Studies....Pages 335-369
Clinical Use of Opioid Antagonists in the Treatment of Alcohol Dependence....Pages 371-386
Preclinical Effects of Opioid Antagonists on Feeding and Appetite....Pages 387-406
CNS Opiate Systems and Eating Disorders....Pages 407-421
Potential Utility of Kappa Ligands in the Treatment of Mood Disorders....Pages 425-444
Opioid Antagonists in the Treatment of Pathological Gambling and Kleptomania....Pages 445-456
Efficacy of Opioid Antagonists in Attentuating Self-Injurious Behavior....Pages 457-472
Pharmacotherapeutic Effects of Opioid Antagonists in Alcohol-Abusing Patients with Schizophrenia....Pages 473-483
Current Issues in the Use of Opioid Antagonists (Naltrexone for Opiate Abuse: A Re-Educational Tool as Well as an Effective Drug)....Pages 487-510
Emergency Room Use of Opioid Antagonists in Drug Intoxication and Overdose....Pages 511-539
Kappa-Opioid Antagonists as Pruritogenic Agents....Pages 541-549
Clinical Effect of Opioid Antagonists on Clinical Pruritus....Pages 551-567
Effects of Opioid Antagonists on l -DOPA-Induced Dyskinesia in Parkinson's Disease....Pages 569-580
Endocrine Effects of Opioid Antagonists....Pages 581-604
Opioid Antagonists in Traumatic Shock: Animal and Human Studies....Pages 605-623
The Efficacy of Opioid Antagonists Against Heatstroke-Induced Ischemia and Injury in Rats....Pages 625-640
A Review of the Opioid System in Cancer Patients and Preliminary Results of Opioid Antagonists in the Treatment of Human Neoplasms....Pages 641-653
Nonclinical Pharmacology of VIVITROL ® : A Monthly Injectable Naltrexone for the Treatment of Alcohol Dependence....Pages 655-674
The Development of Sustained-Release Naltrexone and Clinical Use in Treating Opiate Dependence....Pages 675-688
The Development of ProNeura Technology for the Treatment of Addictions....Pages 689-708
Development of Opioid Transdermal Delivery Systems....Pages 709-728
Intranasal Naloxone for Treatment of Opioid Overdose....Pages 729-739
Back Matter....Pages 741-757
